D-Minus Hemolytic Uremic Syndrome Overview

Save information for later
Sign Up

Learn About D-Minus Hemolytic Uremic Syndrome

What is the definition of D-Minus Hemolytic Uremic Syndrome?
D-minus (diarrhea negative) hemolytic uremic syndrome is an extremely rare, progressive genetic disease characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia).
What are the symptoms of D-Minus Hemolytic Uremic Syndrome?
Symptoms of D-minus hemolytic uremic syndrome may include malaise, fatigue, irritability, lethargy, decreased urine, paleness, scattered bruising, gastrointestinal bleeding, high blood pressure, headaches, double vision, facial paralysis, stroke, seizures, coma, fluid in the lungs, enlarged heart, and kidney failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Minus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous nutrition and fluid replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplant.
Who are the top D-Minus Hemolytic Uremic Syndrome Local Doctors?
Christophe M. Legendre
Elite in D-Minus Hemolytic Uremic Syndrome
Christophe M. Legendre
Elite in D-Minus Hemolytic Uremic Syndrome
Christophe M. Legendre
Paris, FR 

Christophe Legendre practices in Paris, France. Mr. Legendre is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. His top areas of expertise are D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, Kidney Transplant, and Nephrectomy.

Elite in D-Minus Hemolytic Uremic Syndrome
Gianluigi Ardissino
Elite in D-Minus Hemolytic Uremic Syndrome
Gianluigi Ardissino
Via Della Commenda 9, 
Milan, IT 

Gianluigi Ardissino practices in Milan, Italy. Mr. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in D-Minus Hemolytic Uremic Syndrome
Christoph B. Licht
Elite in D-Minus Hemolytic Uremic Syndrome
Christoph B. Licht
555 University Avenue, M5G 1X8, 
Toronto, ON, CA 

Christoph Licht practices in Toronto, Canada. Mr. Licht is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

View All Doctors
What are the latest D-Minus Hemolytic Uremic Syndrome Clinical Trials?
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
Enrollment Status: Recruiting
Publish Date: November 21, 2025

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year. aHUS is a thrombotic microangiopathy (TMA) commonly caused by dysregulation of the complement system, affecting several organs, especially the kidneys. aHUS can be familial or sporadic, and approximately 50%...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
Enrollment Status: Recruiting
Publish Date: November 21, 2025
Intervention Type: Biological, Other
Study Phase: Phase 3

Summary: The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of INM004 in pediatric patients with Hemolytic Uremic Syndrome associated to infection by Shiga toxin-producing Escherichia coli (STEC-HUS).

View All Clinical Trials